SavedAdd your journal

Journals / Solunum Hastalıkları / 2003 / Cilt: 14 - Sayı: 2

Nodular sclerosing Hodgkin's lymphoma occuing in a rheumatoid arthritis patient (case report)

Romatoid artritli bir olguda gelişen nodüler sklerozan tip Hodgkin lenfoma (Olgu sunumu)

Sevin BAŞER
Sibel ÖZTÜRK
Baki YAĞCI
Veli ÇOBANKARA
Fatma FİŞEKÇİ
Pages
142–145
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The physicians caring for RA patients on methotrexate therapy should be vigilant with their patients about developing lymphoma.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Methotrexate is the most widely used second-line treatment in rheumatoid arthritis (RA) because of its efficacy.
📊
Key Findings & Data:The risk factors for RA patients to develop lymphoma while under methotrexate therapy include severe disease, intense immunosupression, genetic predisposition and an increased frequency of latent infection with prooncogenic viruses such as Epstein-Barr virus.
💡
Conclusion & Impact:The physicians caring for RA patients on methotrexate therapy should be vigilant with their patients about developing lymphoma.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Hodgkin hastalığı · Artrit · romatoid

Abstract

Methotrexate is the most widely used second-line treatment in rheumatoid arthritis (RA) because of its efficacy. However, increasing number of cases of lymphoproliferative disorders have been reported in RA patients under methotrexate therapy. The risk factors for RA patients to develop lymphoma while under methotrexate therapy include severe disease, intense immunosupression, genetic predisposition and an increased frequency of latent infection with prooncogenic viruses such as Epstein-Barr virus. We aimed to describe a case of nodular sclerosing Hodgkin's disease developing in a 59 years old woman with seropositive RA treated with oral methotrexate 15 mg/week for 5 years. Computed tomography of the thorax revealed marked hiler lymphadenopathy and interstitial pattern. After discontinuation of methotrexate and adding adriamycin, bleomycin, vinblastine, dacarbazine chemotheraphy, a complete remission was achieved. The physicians caring for RA patients on methotrexate therapy should be vigilant with their patients about developing lymphoma.

Özet

Metotreksat, romatoid artrit (RA)'teki etkinliği nedeniyle ikinci basamak tedavide geniş kullanım alanına sahip bir ajandır. Ancak metotreksat kullanan RA'lı hastalarda artan sayıda lenfoproliferatif hastalıklar bildirilmektedir. Metotreksat tedavisi alan RA'lı hastalardaki lenfoma gelişimi risk faktörleri; ciddi hastalık, hassas immünsüpresyon, genetik predispozisyon ve "Epstein-Barr" virüs gibi proonkojenik virüslerin latent infeksiyonunun artan sıklığına bağlanabilir. Biz de beş yıldır oral olarak 15 mg/hafta da metotreksat kullanan 59 yaşındaki seropozitif RA'lı bayan hastada gelişen nodüler sklerozan tip Hodgkin lenfoma gelişimini sunmayı amaçladık. Olgunun toraks bilgisayarlı tomografisinde belirgin hiler lenfadenapati ve interstisyel patern mevcuttu. Metotreksat tedavisini kesip adriamisin, bleomisin, vinblastin, dakarbazin kemoterapisi uygulanan olguda tam remisyon elde edildi. Metotreksat tedavisi alan RA'lı hastaları takip eden hekimlerin hastalarında olası bir lenfoma gelişimi yönünden uyanık olmaları gerekmektedir.

🔖

Cite This Article

BAŞER, S., ÖZTÜRK, S., YAĞCI, B., ÇOBANKARA, V., FİŞEKÇİ, F. (2003). Nodular sclerosing Hodgkin's lymphoma occuing in a rheumatoid arthritis patient (case report). Solunum Hastalıkları, Cilt: 14 - Sayı: 2, 142–145. https://ajindex.com/articles/318599

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Kame OW, Holly EA, van de Rijn M. A population based, case control study of non-Hodgkin’s lymphoma in patients with rheumatoid arthritis. J Rheumatol 1999;26: 1676-80
  2. Hakulinen T, Isomaki H, Knekt P. Rheumatoid arthritis and cancer studies based on linking nationwide registries in Finland. Am J Med 1985;78(Suppl 1A):29-32
  3. Prior P. Cancer and rheumatoid arthritis: Epidemiologic considerations. Am J Med 1985;78(Suppl 1A):15-21
  4. Symmons DPM. Neoplasms of immune system in rheumatoid arthritis. Am J Med 1985;78(Suppl 1A):22-8
  5. Moseley AC, Lindsley HB, Skikne BS. Reversible methotrexate associated lymphoproliferative disease evolving into hodgkin’s disease. J Rheumatol 2000;27:810-3
  6. Kinlen LJ. Malignancy in autoimmune diseases. J Autoimmun 1992;5(Suppl A):363-71
  7. Kono H, Inokuma S, Matsuzaki Y. Two cases of methotrexate induced lymphomas in rheumatoid arthritis: An association with increased serum IgE. J Rheumatol 1999;26:2249-53
  8. Stewart M, Malkovska V, Krishnan J. Lymhoma in a patient with rheumatoid arthritis receiving methotrexate treathment: Successful treatment with rituximab. Ann Rheum Dis 2001;60:892-3.